attenuator

UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability.

Covidcil-19 binds to the revised attenuator hairpin structure of the SARS-CoV-2 frameshifting element (FSE) with high affinity (Kd = 11 nM). It stabilizes the hairpin's folded state and reduces frameshifting efficiency in cells. Covidcil-19 inhibits viral propagation and reduces viral infectivity by > 3.5 orders of magnitude.

Tifcemalimab (JS004) is a humanised antibody targeting BTLA (B and T lymphocyte attenuator), which binds to BTLA and blocks the interaction between HVEM and BTLA, exhibiting immunomodulatory and antitumour activity.

HVEM(14-39) is a peptide inhibitor of the B and T lymphocyte attenuator (BTLA). It binds to BTLA with a dissociation constant (KD) of 0.102 μM. By modulating BTLA and HVEM expression in T cells, HVEM(14-39) enhances activation and proliferation of T cells and promotes their transition to effector memory T cells. Additionally, HVEM(14-39) can inhibit tumor cell proliferation and induce late apoptosis (apoptosis). This compound has immunomodulatory effects, making it useful for tumor research.